Compositions and methods for the management of hyperproliferative dermatological conditions

A composition, proliferative technology, used in skin diseases, botanical devices and methods, drug combinations, etc.

Active Publication Date: 2008-02-27
SAMI LABS LTD
View PDF11 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] None of the prior art cited above uses natural dual inhibitors of 5-lipoxygenase and human leukocyte elastase in combination with organic selenium supplementation for the treatment of psoriasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for the management of hyperproliferative dermatological conditions
  • Compositions and methods for the management of hyperproliferative dermatological conditions
  • Compositions and methods for the management of hyperproliferative dermatological conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1 Composition of the present invention

[0058] Specific examples of oral formulations of the active ingredient composition of the present invention are listed in Table 1.

[0059] Table 1: Composition of Active Ingredient in Oral Dosage Form

[0060] Active ingredients

content

β-Boswellic acid

64mg

Acetyl-β-Boswellic Acid

48mg

11-keto-β-boswellic acid

24mg

Acetyl-11-keto-β-boswellic acid

32mg

L(+)-Selenomethionine (ground in phosphorus

Calcium Hydrogen Acid)

20mg

[0061] The preparation can be made into capsules, tablets, powders, sustained-release capsules (spansules) or other dosage forms, while using common excipients and additives for making the above dosage forms.

[0062] Examples of formulations for topical use are listed in Table 2.

[0063] Table 2: Cream compositions for topical use

[0064] Composition %(w / w)

[0065] Purified water 60.00

[0066] Carbomer...

Embodiment 2

[0087] Example 2 Treatment of human psoriasis patients using the compositions and methods of the present invention.

[0088] Twelve patients (six males and one female) aged 18 to 65 years with primary plaque-like and second-grade circular, polycyclic, and measles-like lesions with Symptoms include itching, peeling skin, and bleeding from abrasions.

[0089] Patients were orally administered tablets containing 400 mg boswellic acid and 100 mcg of selenium in the form of L(+) selenomethionine, and were also treated with a topical cream containing 400 mg boswellic acid.

[0090] The daily dosing regimen followed was 1 tablet as above, with topical cream as above, three times daily for 150 days. PASI values ​​(Psoriasis Area Severity Index) taking into account body surface area and erythema (red), induration (thickness) and scaling, were assessed at four-week intervals. Serum biochemical parameters were also assessed.

[0091] Physical psoriasis patients were photographed at th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention describes compositions and methods for the management of hyperproIiferative skin conditions such as psoriasis. The preferential composition contains a natural leukotriene inhibitor selected from Boswellia serrata gum resin, its extractives, isolates or derivatives in combination with a bioavailable organic selenium nutritional supplement. These compositions are administered orally and topically to the individual human or animal in need of treatment at optimal levels to manifest the desired benefits, with no untoward side effects.

Description

technical field [0001] The present invention relates to compositions and methods for treating hyperproliferative skin diseases such as psoriasis and their associated conditions. The compositions described herein comprise a natural leukotriene inhibitor selected from Boswellia serrata gum resin, extracts, isolates or derivatives thereof, in combination with a bioavailable organic selenium nutritional supplement. These compositions are administered orally and topically to humans or animals in need of treatment in optimum doses and suitable dosage forms to achieve desired effects without adverse side effects. Background technique [0002] Psoriasis is a chronic skin disease characterized by recurrent attacks of highly visible red spots covered by a thin, flaking, silvery epidermis. In psoriasis, the epidermis of the skin suffers from devastating lesions caused by genetic variations in the immune system triggered by stress and environmental factors. There is an overgrowth of i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A01N25/00A01N65/00A61K38/00A61K45/00
CPCA61K33/04A61K31/28A61K36/324A61K45/06A61P17/00A61P17/06A61P43/00
Inventor 穆罕麦德·马吉德萨巴拉克什米·普拉卡什
Owner SAMI LABS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap